Real-world efficacy, safety, and clinical outcomes of ombitasvir/paritaprevir/ritonavir +/- dasabuvir +/- ribavirin combination therapy in patients with hepatitis C virus genotype 1 or 4 infection: The Turkey experience experience

AYGEN, BİLGEHAN; DEMİRTÜRK, NEŞE; YILDIZ, ORHAN; ÇELEN, MUSTAFA; Celik, Ilhami; Barut, Sener; URAL, ONUR; Batirel, Ayse; Mistik, Resit; Simsek, Funda; Asan, Ali; ERSÖZ, GÜLDEN; Turker, Nesrin; Bilgin, Huseyin; Kinikli, Sami; KARAKEÇİLİ, FARUK; ZARARSIZ, GÖKMEN

doi:10.5152/tjg.2020.19197

Real-world efficacy, safety, and clinical outcomes of ombitasvir/paritaprevir/ritonavir +/- dasabuvir +/- ribavirin combination therapy in patients with hepatitis C virus genotype 1 or 4 infection: The Turkey experience experience

Atıf İçin Kopyala

AYGEN B., DEMİRTÜRK N., YILDIZ O., ÇELEN M. K., Celik I., Barut S., ...Daha Fazla

TURKISH JOURNAL OF GASTROENTEROLOGY, cilt.31, sa.4, ss.305-317, 2020 (SCI-Expanded)

Yayın Türü: Makale / Tam Makale
Cilt numarası: 31 Sayı: 4
Basım Tarihi: 2020
Doi Numarası: 10.5152/tjg.2020.19197
Dergi Adı: TURKISH JOURNAL OF GASTROENTEROLOGY
Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus, EMBASE, MEDLINE, TR DİZİN (ULAKBİM)
Sayfa Sayıları: ss.305-317
Bursa Uludağ Üniversitesi Adresli: Evet

Özet

Background/Aims: mbitasvir/paritaprevir/ritonavir (OMV/PTV/r) +/- dasabuvir (DSV) +/- ribavirin (RBV) combination has demonstrated excellent rates of sustained virologic response (SVR) and a very good safety profile in patients with the chronic hepatitis C virus (HCV) genotype 1 or 4 infections. We aimed to investigate the effectiveness and safety of OMV/PTV/r +/- DSV +/- RBV combination regimen in a real-world clinical practice.